A Pharmacogenetic Study of Psoriasis Risk Variants in a Greek Population and Prediction of Responses to Anti-TNF-α and Anti-IL-12/23 Agents

Abstract

This study is the first in the field of pharmacogenetics in Greek psoriasis patients. Further, larger studies are required to validate our findings and replicate them in various populations.

Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis

“…[33][34][35][36][37][38][39][40][41][42][43] For all significant associations, except TLR9 (rs352139) and LY96 (rs11465996), similar tendencies were observed for ORs for each of the anti-TNF agents (data available on request). To our knowledge, this is one of the largest cohorts for evaluation of response in patients treated with ustekinumab 44,45 and the second largest for evaluation of anti-TNF; only a Canadian study (also involving treatment primarily for psoriatic arthritis) had more patients.…”

Challenges of biological therapy in patients with pustular psoriasis coexisting with psoriatic arthritis

“…Prowadzone są także badania, które mają udowodnić, że odpowiedź na leczenie może mieć podło-że genetyczne [36][37][38][39][40]. Jest ono związane z polimorfizmami genu TNF, receptora TNF-1B (TNFR1B) oraz genu TNFAIB3, jak również z polimorfizmami innych genów.…”

“…Studies are also conducted in order to verify whether response to treatment may be genetically conditioned [36][37][38][39][40]. It is associated with polymorphisms of the TNF gene, TNF receptor 1B (TNFR1B) and TNFAIB3 gene, as well as polymorphisms of other genes.…”

Genetic Influences on Pharmacological Interventions in Psoriasis

“…Patients with HLA-C * 05 were linked to achieving PASI 75 response when treated with etanercept [29]. HLA-C SNP rs10484554 was associated with good response to anti-TNF alpha agents, especially adalimumab [39]. And lastly, HLA-DRB1 encoding SE alleles * 0101 and * 0404 were both associated with good response to etanercept [29].…”

“…However, a few studies found associations with different HLA-C genes. HLA-C SNP rs10484554 was associated with good response to anti-TNF therapy but not with ustekinumab [39]. This study looked at the use of biologics and response for 6 months of therapy, and genotype frequency was analyzed after.…”